[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Borucki U, Metze D: Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology; 2003;207(3):326-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical treatment of lentigo maligna melanoma with imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / administration & dosage. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Facial Neoplasms / drug therapy. Facial Neoplasms / pathology. Female. Follow-Up Studies. Humans. Ointments. Treatment Outcome

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14571081.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; P1QW714R7M / imiquimod
  •  go-up   go-down


2. Choi H, Ahn S, Lee BG, Chang I, Hwang JS: Inhibition of skin pigmentation by an extract of Lepidium apetalum and its possible implication in IL-6 mediated signaling. Pigment Cell Res; 2005 Dec;18(6):439-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of effective skin-lightening agents is an increasingly important area of research aimed at the treatment of hyperpigmentation induced by UV irradiation or by medical conditions such as melasma, postinflammatory melanoderma and solar lentigo.
  • Although some inhibit tyrosinase, identifying and understanding the mechanisms of action of other agents is an important goal if more effective pigmentation inhibitors are to be developed.
  • We present here that an extract of Lepidium apetalum (ELA) decreased UV-induced skin pigmentation in brown guinea pigs and melanogenesis of HM3KO human melanoma cells.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280009.001).
  • [ISSN] 0893-5785
  • [Journal-full-title] Pigment cell research
  • [ISO-abbreviation] Pigment Cell Res.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Plant Extracts; 0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


3. Metcalf S, Crowson AN, Naylor M, Haque R, Cornelison R: Imiquimod as an antiaging agent. J Am Acad Dermatol; 2007 Mar;56(3):422-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatologic diseases.
  • Several published reports have validated the benefit of imiquimod therapy for actinic keratoses and superficial melanoma and nonmelanoma skin cancers.
  • There is, however, limited evidence demonstrating the use of topical imiquimod application as an antiaging treatment.
  • OBJECTIVES: We examined the effectiveness of imiquimod 5% cream in the treatment of photoaging by evaluating pretreatment and posttreatment biopsy specimens and documenting the histologic changes.
  • METHODS: This study represents an extension of an earlier project in our department in which patients with biopsy-proven lesions of lentigo maligna (LM) were recruited from a university dermatology service, a hospital, and referrals from private practitioners for an open-labeled efficacy trial with daily topical application of 5% imiquimod for 3 months.
  • Biopsy of clinically affected skin was carried out on all patients before and after treatment.
  • CONCLUSION: Topical imiquimod appears to induce reparative changes to the epidermis and the dermal collagen table in chronically sun-damaged skin associated with LM, indicating its potential use as an antiaging treatment.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / physiopathology. Skin Aging / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology
  • [MeSH-minor] Cell Count. Collagen / metabolism. Dermis / metabolism. Dermis / pathology. Drug Administration Schedule. Epidermis / metabolism. Epidermis / pathology. Humans. Melanins / metabolism. Melanocytes / pathology. Ointments

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184874.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Melanins; 0 / Ointments; 9007-34-5 / Collagen; 99011-02-6 / imiquimod
  •  go-up   go-down


Advertisement
4. Wolf IH, Cerroni L, Kodama K, Kerl H: Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol; 2005 Apr;141(4):510-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
  • BACKGROUND: Surgical excision is the treatment of choice for lentigo maligna (LM), or melanoma in situ.
  • Topical application of imiquimod, a local immune response modifier, is a novel therapeutic approach that leads to LM tumor clearance.
  • OBSERVATIONS: Six biopsy-proven cases of LM from 5 patients (age range, 67-80 years) in whom standard surgical therapy was contraindicated were enrolled in the study.
  • Time to complete clearing varied from 5 to 13 weeks based on both clinical and histopathologic findings.
  • The inflammatory infiltrate following imiquimod treatment consisted of T-helper lymphocytes mixed with a significant number of cytotoxic cells and monocytes or macrophages.
  • In all patients, erythema and erosions occurred at the treated area 2 to 4 weeks after initiation of imiquimod therapy.
  • CONCLUSIONS: Topical imiquimod appears to be an excellent therapeutic option for LM.
  • Imiquimod can be added to the list of therapeutic approaches for carefully selected patients with LM.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Pilot Projects. Risk Assessment. Single-Blind Method. Treatment Outcome

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Apr;142(4):530-1 [16618884.001]
  • (PMID = 15837872.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


5. Thomas L, Dalle S: Dermoscopy provides useful information for the management of melanonychia striata. Dermatol Ther; 2007 Jan-Feb;20(1):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, the presence of a brown pigmentation overlaid by longitudinal lines irregular in their thickness, spacing, color, or parallelism is highly in favor of a melanoma.
  • Gray homogeneous lines are observed in case of lentigo, lentiginoses, ethnic or drug-induced pigmentations, and in post-traumatic pigmentations.
  • Blood spots are characterized by their round-shaped proximal edge and their filamentous distal edge and are highly suggestive of subungual hemorrhages.
  • Dermoscopic examination of the free edge of the nail plate gives information on the lesion location; pigmentation of the dorsum of the nail plate is in favor of a proximal nail matrix lesion, whereas pigmentation the lower part of the nail edge is in favor of a lesion of the distal matrix.
  • [MeSH-minor] Dermoscopy. Diagnosis, Differential. Humans. Melanoma / diagnosis. Melanoma / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403255.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Number-of-references] 14
  •  go-up   go-down


6. Menichini F, Tundis R, Loizzo MR, Bonesi M, Provenzano E, de Cindio B, Menichini F: In vitro photo-induced cytotoxic activity of Citrus bergamia and C. medica L. cv. Diamante peel essential oils and identified active coumarins. Pharm Biol; 2010 Sep;48(9):1059-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The search for innovative therapeutic approaches is gaining more interest in clinical oncology.
  • In order to evaluate the cytotoxic activity two melanoma models, such as amelanotic melanoma C32 and malignant melanoma A375, were used.
  • This phototoxicity may be considered as a treatment option in some cases of lentigo maligna or lentigo maligna melanoma.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Drug Discovery. Drug Evaluation, Preclinical. Gas Chromatography-Mass Spectrometry. Humans. Inhibitory Concentration 50. Melanoma / drug therapy. Melanoma, Amelanotic / drug therapy. Methoxsalen / analogs & derivatives. Methoxsalen / analysis. Methoxsalen / chemistry. Methoxsalen / pharmacology. Methoxsalen / radiation effects. Photochemotherapy. Phytotherapy. Time Factors. Ultraviolet Rays

  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • Hazardous Substances Data Bank. 5-METHOXYPSORALEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690896.001).
  • [ISSN] 1744-5116
  • [Journal-full-title] Pharmaceutical biology
  • [ISO-abbreviation] Pharm Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins; 0 / Oils, Volatile; 4FVK84C92X / 5-methoxypsoralen; JWE1QQ247N / 5,7-dimethoxycoumarin; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


7. Lang PG: Current concepts in the management of patients with melanoma. Am J Clin Dermatol; 2002;3(6):401-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the management of patients with melanoma.
  • Melanoma is a significant health problem.
  • Despite public education and free cancer screenings, the incidence and mortality of melanoma continues to rise; however, many currently diagnosed melanomas are thin lesions, suggesting that education and awareness is having an impact.
  • Although large congenital nevi may be precursors of melanoma, small and medium congenital nevi have an insignificant risk for melanoma development.
  • Large congenital nevi, which are axial in location, appear to be more likely to develop melanoma and are associated with melanocytosis and melanoma of the CNS, both of which portend a poor prognosis.
  • Lymphoscintigraphy and sentinel node biopsy have replaced elective node dissections, thus decreasing the morbidity associated with the surgical management of melanoma.
  • For example, cryosurgery or radiation therapy may be indicated in the frail, elderly individual with a large facial lentigo maligna.
  • Mohs surgery is the treatment of choice for head and neck melanomas and those located in areas where maximum preservation of tissue is required and for desmoplastic and acral lentiginous melanomas.
  • Much more work remains in the area of adjuvant therapy, chemotherapy, and immunotherapy.
  • Dacarbazine remains the drug of choice in disseminated melanoma, but remissions are usually short lived.
  • Although high dose interferon increases disease-free and overall survival in some patients, it remains a controversial drug which is not easily tolerated.
  • In the new staging system for melanoma, ulceration is second only to Breslow's thickness.
  • Except for lesions <1mm thick, the Clark's level of invasion has been de-emphasized.
  • [MeSH-major] Melanoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Incidence. Interferon-alpha / therapeutic use. Lymph Node Excision. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Prognosis. Recombinant Proteins. Risk Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12113649.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 285
  •  go-up   go-down


8. Little JW: Melanoma: etiology, treatment, and dental implications. Gen Dent; 2006 Jan-Feb;54(1):61-66; quiz, 67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma: etiology, treatment, and dental implications.
  • Melanoma is one of the most serious skin cancers.
  • Melanoma also can arise from melanocytes located in other regions of the body such as the eye, meninges, digestive tract, mucosal surfaces, or lymph nodes.
  • There are no proven causes of melanoma but the most commonly associated factor is episodic exposure to the sun.
  • Melanoma is a common cancer that has been increasing in incidence for the last 35 years.
  • The median age at the time of diagnosis is 53 years.
  • Five-year survival rates for melanoma of the skin have been increasing since 1976.
  • There are four types of melanoma: superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lintiginous melanoma.
  • Clinical signs indicating possible melanoma are asymmetry, border irregularity, color variation, increase in diameter, elevation, ulceration, and bleeding of pigmented lesions.
  • Treatment consists of surgical excision, lymph node dissection, limb perfusion, regional chemotherapy infusion, radiation, intralesional immunotherapy, systemic chemotherapy, and/or interferon-alpha, depending on the staging of the melanoma.
  • Lesions suspected of melanoma must be biopsied, which usually involves referral of the patient.
  • [MeSH-major] Head and Neck Neoplasms. Melanoma. Mouth Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494125.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


9. Göhl J, Hohenberger W, Merkel S: [Malignant melanoma]. Chirurg; 2009 Jun;80(6):559-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma].
  • [Transliterated title] Malignes Melanom.
  • There are four histological types: superficial spreading melanoma, nodular melanoma, acrolentiginous melanoma and lentigo maligna melanoma.
  • In the case of lymph node metastases therapeutic dissection is recommended, in patients with in-transit metastases of the extremities hyperthermic isolated limb perfusion with cytostatic agents may be indicated.
  • Adjuvant, neoadjuvant and palliative procedures, such as radiotherapy, chemotherapy and immunotherapy are additional treatment options.
  • [MeSH-major] Melanoma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Prognosis. Skin / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):119-26 [12925966.001]
  • [Cites] Cancer Invest. 2008 Jun;26(5):516-34 [18568775.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1983-91 [11064356.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):280-90 [11586069.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3445-55 [18612161.001]
  • [Cites] J Exp Med. 2002 May 20;195(10):1279-88 [12021308.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):659-64 [17870430.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):607-18 [10348291.001]
  • [Cites] Dermatol Surg. 2003 Apr;29(4):366-74 [12656815.001]
  • (PMID = 19444395.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Davids LM, Kleemann B, Kacerovská D, Pizinger K, Kidson SH: Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B; 2008 May 29;91(2-3):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells.
  • Although photodynamic mechanisms (i.e. through endogenous photosensitizers) play a role in UVA phototherapy for the treatment of skin disorders such as eczema and psoriasis, photodynamic therapy employing exogenous photosensitizers are currently being used only for the treatment of certain forms of non-melanoma skin cancers and actinic keratoses.
  • We show that an exposure to 1 microM UVA-activated hypericin does not bring about cell death, while 3 microM activated hypericin induces a necrotic mode of cell death in pigmented melanoma cells and melanocytes and an apoptotic mode of cell death in non-pigmented melanoma cells and keratinocytes.
  • In contrast, this study shows that cells that do not contain melanosomes (non-pigmented melanoma cells and keratinocytes) die by apoptosis.
  • This work suggests that UVA is effective in activating hypericin and that this phototoxicity may be considered as treatment option in some cases of lentigo maligna or lentigo maligna melanoma that are too large for surgical resection.
  • [MeSH-major] Keratinocytes / drug effects. Melanocytes / drug effects. Melanoma / pathology. Perylene / analogs & derivatives. Photochemotherapy / methods. Photosensitizing Agents / toxicity. Skin / cytology
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3 / metabolism. Caspase 7 / metabolism. Cell Death / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Humans. Intracellular Space / metabolism. Necrosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342534.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  •  go-up   go-down


11. Basarab T, Millard TP, McGregor JM, Barker JN: Atypical pigmented lesions following extensive PUVA therapy. Clin Exp Dermatol; 2000 Mar;25(2):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical pigmented lesions following extensive PUVA therapy.
  • We report a 38-year-old woman with psoriasis who developed multiple atypical lentigines following psoralen photochemotherapy (PUVA).
  • The lentigines first appeared 12 years ago, 3 years after she commenced intermittent PUVA treatment.
  • Histology of a representative lesion was consistent with a PUVA lentigo and no atypical melanocytes were seen.
  • At present, a link between malignant melanoma and PUVA lentigines has not been established.
  • [MeSH-major] Lentigo / etiology. PUVA Therapy / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Psoriasis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2001 Jul;26(5):459 [11488842.001]
  • (PMID = 10733639.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


12. Bogenrieder T, Weitzel C, Schölmerich J, Landthaler M, Stolz W: Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology; 2002;205(2):174-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
  • Induction of multiple eruptive dermal and atypical melanocytic naevi has frequently been reported in children with malignant haematological diseases and chemotherapy-induced immunosuppression.
  • This is the first report of an adult patient to develop multiple eruptive melanocytic skin lesions while undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Carcinoma / drug therapy. Carcinoma / secondary. Colorectal Neoplasms / pathology. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Hutchinson's Melanotic Freckle / chemically induced. Prodrugs / adverse effects. Skin Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Capecitabine. Fluorouracil. Humans. Male. Melanoma / physiopathology. Middle Aged. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / pathology. Nevus, Pigmented / chemically induced. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12218237.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL: Treatment of lentigo maligna with topical imiquimod. Br J Dermatol; 2003 Nov;149 Suppl 66:66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lentigo maligna with topical imiquimod.
  • A published case report and anecdotal experience suggested that topical imiquimod is an effective treatment for stage 0 melanoma (lentigo maligna).
  • To gauge the efficacy of this therapy, we undertook a trial of topical imiquimod in 30 subjects with histologically confirmed lentigo maligna.
  • Thirty subjects with lentigo maligna were recruited for an open-labelled efficacy trial with daily topical application of imiquimod 5% cream for 3 months.
  • In order to determine an initial response rate, a four-quadrant biopsy was carried out on all patients 1 month after cessation of treatment, targeting the most clinically and dermatoscopically suspicious areas.
  • Of 28 evaluable subjects who have completed the 3-month treatment phase, 26 (93%) were complete responders and two were treatment failures at the time of the 4-quadrant biopsy.
  • Over 80% of the 28 subjects that completed treatment have been followed for more than 1 year with no relapses.
  • The results of this study demonstrate that topical imiquimod produces a high complete response rate in lentigo maligna when applied daily for 3 months.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy
  • [MeSH-minor] Administration, Topical. Cytokines / adverse effects. Drug Administration Schedule. Erythema / chemically induced. Female. Follow-Up Studies. Humans. Male. Ointments. Skin Ulcer / chemically induced. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616356.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Cytokines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement